Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 8.9 |
| Analyst target | 9.0 |
- ▸Attractively valued
SRTA · Why this verdict
Why Strata Critical Medical (SRTA) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score6.4/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue grew 87% year-over-year, and the peer comparison notes flag the company as both an industry growth leader and best-in-class on margins. Growth breakdown | Revenue growth should remain above 40% YoY over the next several quarters if the growth trajectory holds. | →Stable |
| CounterHigh growth off a small base for a recently-formed medical services company can decelerate sharply as the base normalizes. | ||
The company posts strong 21% margins, but earnings quality carries a red flag at -51% FCF-to-net-income conversion, alongside a weak Piotroski F-Score of 3/9. Quality breakdown | FCF-to-net-income conversion should turn positive within 12 months if reported earnings quality is genuine. | →Stable |
| CounterNegative FCF-to-net-income conversion alongside high revenue growth is common for scaling healthcare service businesses investing heavily in capacity. | ||
The engine calculates a 4.3x asymmetry ratio with 45.3% upside potential against a 10.5% downside per the engine's risk framework. Reward-to-risk math | Price should progress toward the $7.86 take-profit target over the next 12 months if the setup resolves favorably. | →Stable |
| CounterA range-bound technical setup suggests the stock currently lacks directional conviction that would support reaching the take-profit target. | ||
The company has split evenly on earnings over the last 4 quarters, with an extremely volatile average surprise of -190.16%. Earnings | The average surprise magnitude should narrow toward single digits as the company's small earnings base normalizes and forecasting improves. | →Stable |
| CounterA small absolute EPS base structurally inflates percentage surprises and may not reflect genuine forecasting or execution problems. | ||
Insiders have been net sellers over the trailing 90 days, with 7 sell transactions totaling $802,594 in net value and zero buys, a moderate-severity bearish signal. Insider | Insider selling intensity should decline or buying should resume over the next quarter. | →Stable |
| CounterThe sale total represents only 0.171% of market cap and could reflect routine diversification rather than a negative view on the business. | ||
Revenue grew 87% year-over-year, and the peer comparison notes flag the company as both an industry growth leader and best-in-class on margins.
→StableGrowth breakdown
- Expectation
- Revenue growth should remain above 40% YoY over the next several quarters if the growth trajectory holds.
CounterHigh growth off a small base for a recently-formed medical services company can decelerate sharply as the base normalizes.
The company posts strong 21% margins, but earnings quality carries a red flag at -51% FCF-to-net-income conversion, alongside a weak Piotroski F-Score of 3/9.
→StableQuality breakdown
- Expectation
- FCF-to-net-income conversion should turn positive within 12 months if reported earnings quality is genuine.
CounterNegative FCF-to-net-income conversion alongside high revenue growth is common for scaling healthcare service businesses investing heavily in capacity.
The engine calculates a 4.3x asymmetry ratio with 45.3% upside potential against a 10.5% downside per the engine's risk framework.
→StableReward-to-risk math
- Expectation
- Price should progress toward the $7.86 take-profit target over the next 12 months if the setup resolves favorably.
CounterA range-bound technical setup suggests the stock currently lacks directional conviction that would support reaching the take-profit target.
The company has split evenly on earnings over the last 4 quarters, with an extremely volatile average surprise of -190.16%.
→StableEarnings
- Expectation
- The average surprise magnitude should narrow toward single digits as the company's small earnings base normalizes and forecasting improves.
CounterA small absolute EPS base structurally inflates percentage surprises and may not reflect genuine forecasting or execution problems.
Insiders have been net sellers over the trailing 90 days, with 7 sell transactions totaling $802,594 in net value and zero buys, a moderate-severity bearish signal.
→StableInsider
- Expectation
- Insider selling intensity should decline or buying should resume over the next quarter.
CounterThe sale total represents only 0.171% of market cap and could reflect routine diversification rather than a negative view on the business.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Strata Critical Medical shows standout revenue growth and a favorable engine-calculated risk/reward setup, but earnings quality red flags, a volatile earnings track record, and ongoing insider selling temper the bullish growth narrative.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.2 |
| Op margin | 0.0 |
| Net margin | 10.0 |
| Current ratio | 7.1 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Piotroski F | 4.4 |
- ▸Strong margins: 21%
- ▸Earnings quality RED FLAG: -51% FCF/NI
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 87% YoY
Momentum
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 8.3 |
| MACD | 3.0 |
| OBV | 10.0 |
| MA position | 4.0 |
| Volume | 0.7 |
- ▸Oversold in uptrend (RSI 25)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.1 |
| Price target | 9.9 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (4.0) — signal dampened
- ▸Analyst upside: 79%
Insider
5.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 10.0 |
- ▸Notable insider selling — $802,594 (0.171% of mkt cap)
- ▸Institutions accumulating
Peer rank
6.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.1 |
| quality rank | 5.5 |
| growth rank | 9.4 |
- ▸Best-in-class margins
- ▸Industry growth leader
Technical
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.6 |
| support resistance | 8.8 |
| 52w position | 5.9 |
Risk (lower is worse)
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.2 |
| days to cover | 3.1 |
| volatility | 0.2 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 2.6 |
| debt equity | 9.9 |
- ▸High IV: 98%
- ▸Above max pain $2
Catalyst
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:5.2>=4.5
- ASYMMETRY:5.3>=1.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:28d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- MOMENTUM:5.2<5.5 (soft — BUY_NOW allowed but watch)
- INSIDER:0.17%=MODERATE
Reward-to-Risk
5.32
Upside
+52.4%
Downside
9.8%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.5B) below institutional reach
SuitabilityAggressive — Beta 2.22>1.3, MCap $0.5B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Growth at 10.0, Value at 9.0, and Technical at 7.8; the weakest are Quality at 3.1, Catalyst at 3.3, and Risk (lower is worse) at 3.3. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 5.32 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Strong Revenue Growth Industry Leader
Trip ifRevenue growth falls below 40% YoY for 2 consecutive quarters.
- P2Favorable Risk Reward Asymmetry
Trip ifPrice falls below the $5.03 stop-loss, invalidating the 4.3x asymmetry setup.
- P3Earnings Quality Red Flag
Trip ifFCF-to-net-income conversion exceeds 0% for 2 consecutive quarters.
- P4Volatile Earnings Track Record
Trip ifThe average earnings surprise magnitude falls below 20 percentage points for 2 consecutive quarters.
- P5Insider Selling Signal
Trip ifInsider buying exceeds $500,000 over a rolling 90-day window, reversing the bearish signal.